BG101892A - Цитостатици, модифицирани с въглехидрати - Google Patents

Цитостатици, модифицирани с въглехидрати

Info

Publication number
BG101892A
BG101892A BG101892A BG10189297A BG101892A BG 101892 A BG101892 A BG 101892A BG 101892 A BG101892 A BG 101892A BG 10189297 A BG10189297 A BG 10189297A BG 101892 A BG101892 A BG 101892A
Authority
BG
Bulgaria
Prior art keywords
sugar
cytostatics
modified
modified cytostatics
tumourspecific
Prior art date
Application number
BG101892A
Other languages
English (en)
Other versions
BG63048B1 (bg
Inventor
Hans - Georg LERCHEN
Dem Bruch Karsten Von
Uwe Petersen
Joerg Baumgarten
Norbert Piel
Horst-Peter Antonicek
Walter Weichel
Michael Sperzel
Klaus Bremm
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of BG101892A publication Critical patent/BG101892A/bg
Publication of BG63048B1 publication Critical patent/BG63048B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретението се отнася до цитостатици, които чрез модифициране с въглехидрати се проявяват като туморспецифични. Подходящи пространствени връзки осигуряват серумна стабилност и вътреклетъчно действие.
BG101892A 1995-04-04 1997-09-16 Цитостатици, модифицирани с въглехидрати BG63048B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19512484A DE19512484A1 (de) 1995-04-04 1995-04-04 Kohlenhydratmodifizierte Cytostatika
PCT/EP1996/001279 WO1996031532A1 (de) 1995-04-04 1996-03-22 Kohlenhydratmodifizierte cytostatika

Publications (2)

Publication Number Publication Date
BG101892A true BG101892A (bg) 1998-05-29
BG63048B1 BG63048B1 (bg) 2001-02-28

Family

ID=7758679

Family Applications (1)

Application Number Title Priority Date Filing Date
BG101892A BG63048B1 (bg) 1995-04-04 1997-09-16 Цитостатици, модифицирани с въглехидрати

Country Status (27)

Country Link
US (1) US6271342B1 (bg)
EP (1) EP0819135B1 (bg)
JP (1) JPH11502860A (bg)
KR (1) KR19980703591A (bg)
CN (1) CN1185786A (bg)
AT (1) ATE186738T1 (bg)
AU (1) AU713466B2 (bg)
BG (1) BG63048B1 (bg)
BR (1) BR9604825A (bg)
CA (1) CA2217164A1 (bg)
CZ (1) CZ291098B6 (bg)
DE (2) DE19512484A1 (bg)
DK (1) DK0819135T3 (bg)
EE (1) EE03619B1 (bg)
ES (1) ES2140078T3 (bg)
GR (1) GR3032605T3 (bg)
HU (1) HUP9800513A3 (bg)
IS (1) IS1822B (bg)
MX (1) MX9707613A (bg)
NO (1) NO974564L (bg)
NZ (1) NZ305855A (bg)
PL (1) PL183574B1 (bg)
RU (1) RU2170234C2 (bg)
SK (1) SK281785B6 (bg)
TW (1) TW384290B (bg)
UA (1) UA61054C2 (bg)
WO (1) WO1996031532A1 (bg)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2267328A1 (en) * 1996-09-30 1998-04-09 Bayer Aktiengesellschaft Glycoconjugates from modified camptothecin derivates (20-o-linkage)
DE19640970A1 (de) * 1996-10-04 1998-04-16 Bayer Ag Modifizierte Cytostatika
JP3101710B2 (ja) 1997-02-28 2000-10-23 工業技術院長 硫酸化オリゴ糖化合物
ID23424A (id) * 1997-05-14 2000-04-20 Bayer Ag Glikokonjugat dari 20(s)-kamptotesin
US6387928B1 (en) 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
SK286420B6 (sk) 1997-09-15 2008-09-05 The Procter & Gamble Company Zlúčenina so štruktúrou chinolónu, farmaceutický prostriedok s jej obsahom a jej použitie
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US7220824B1 (en) * 2000-08-28 2007-05-22 Bayer Aktiengesellschaft Integrin-mediated drug targeting
EP1219634A1 (en) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Cytostatic-glycoconjugates having specifically cleavable peptidic linking units
EP1238678A1 (en) * 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzyme-activated cytostatic conjugates with integrin ligands
WO2003040093A2 (de) * 2001-11-09 2003-05-15 Bayer Healthcare Ag Isotopencodierte affinitätsmarker 2
US7199149B2 (en) * 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
CA2647457C (en) 2006-03-28 2011-05-24 The Procter & Gamble Company A hydride reduction process for preparing quinolone intermediates
MX2008012488A (es) 2006-03-28 2008-10-10 Procter & Gamble Un proceso de acoplamiento para preparar intermedios de quinolona.
EP2001862B1 (en) 2006-03-28 2011-04-27 Warner Chilcott Company, LLC Malate salts, and polymorphs of (3s,5s)-7-[3-amino-5-methyl-piperidinyl]-1-cyclopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
AU2016359235B2 (en) 2015-11-25 2022-09-15 Ligachem Biosciences Inc. Antibody-drug conjugates comprising branched linkers and methods related thereto
AU2016359230B2 (en) 2015-11-25 2020-04-23 Ligachem Biosciences Inc. Conjugates comprising self-immolative groups and methods related thereto
CA3058360A1 (en) 2017-03-29 2018-10-04 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
CN112601555A (zh) 2018-05-09 2021-04-02 乐高化学生物科学股份有限公司 与抗cd19抗体药物结合物相关的组合物和方法
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
JP7820508B2 (ja) * 2021-10-06 2026-02-25 サムヤン コーポレイション 飽和フロジオキシン誘導体化合物及びその二次電池用添加剤としての使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5977356A (ja) * 1982-06-30 1984-05-02 Fuji Photo Film Co Ltd 螢光アツセイ用多層分析要素およびそれを用いる螢光アツセイ法
DE3611194A1 (de) * 1986-04-04 1987-10-08 Bayer Ag Cancerostatisches mittel
ATE106898T1 (de) * 1987-03-26 1994-06-15 Neorx Corp Metall-radionuklid-markierte proteine und glykoproteine zur diagnose und therapie.
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4980343A (en) * 1988-10-27 1990-12-25 Bayer Aktiengesellschaft Aminooxodihydroisoindoloquinazoline carcinostatic agents
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
ZA909847B (en) * 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5160727A (en) * 1990-02-13 1992-11-03 Warner-Lambert Company Tumor cell sensitization method using quinazolinedione derivatives
US5965695A (en) 1990-05-15 1999-10-12 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
US5420297A (en) 1990-10-24 1995-05-30 Fujisawa Pharmaceutical Co., Ltd. Peptides having substance P antagonistic activity
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DE4106101A1 (de) * 1991-02-27 1992-09-03 Bayer Ag Fucose-markierte cytostatika
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
FR2676058B1 (fr) 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4120646A1 (de) 1991-06-22 1992-12-24 Bayer Ag 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate
DE59209745D1 (de) 1991-11-29 1999-10-21 Hoechst Ag Peptide mit insulinartiger Wirkung
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
NZ248332A (en) 1992-08-07 1995-01-27 Sankyo Co Hiv protease inhibitor and its use
US5872207A (en) 1992-09-04 1999-02-16 Sanofi Pharmaceuticals, Inc. N-terminal-marked peptides immobilized on glass beads and method of preparation and method of use thereof
IL106998A0 (en) 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
US5576298A (en) 1992-11-30 1996-11-19 Research And Development Institute, Inc. At Montana State University Peptides from pseudomonas syringae possessing broad-spectrum antibiotic activity
SE9300012D0 (sv) 1993-01-05 1993-01-05 Astra Ab New peptides
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
WO1995010296A1 (en) * 1993-10-12 1995-04-20 Glycomed Incorporated A library of glyco-peptides useful for identification of cell adhesion inhibitors
US5610145A (en) 1994-04-15 1997-03-11 Warner-Lambert Company Tachykinin antagonists
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
FR2729668A1 (fr) 1995-01-23 1996-07-26 Adir Nouveaux derives de mercaptoalcanoyldipeptides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5677286A (en) * 1995-04-27 1997-10-14 The University Of Michigan Glycosylated analogs of camptothecin
US6143931A (en) 1997-04-16 2000-11-07 Arqule, Inc. Synthesis and use of α-ketoamide derivatives and arrays

Also Published As

Publication number Publication date
IS1822B (is) 2002-10-01
WO1996031532A1 (de) 1996-10-10
CZ314397A3 (cs) 1998-01-14
RU2170234C2 (ru) 2001-07-10
EP0819135A1 (de) 1998-01-21
GR3032605T3 (en) 2000-05-31
ATE186738T1 (de) 1999-12-15
CN1185786A (zh) 1998-06-24
UA61054C2 (en) 2003-11-17
IS4562A (is) 1997-09-18
HUP9800513A2 (hu) 1998-06-29
EE03619B1 (et) 2002-02-15
NZ305855A (en) 1999-11-29
TW384290B (en) 2000-03-11
AU713466B2 (en) 1999-12-02
SK281785B6 (sk) 2001-07-10
PL322681A1 (en) 1998-02-16
CZ291098B6 (cs) 2002-12-11
EE9700258A (et) 1998-04-15
PL183574B1 (pl) 2002-06-28
JPH11502860A (ja) 1999-03-09
AU5397696A (en) 1996-10-23
KR19980703591A (ko) 1998-11-05
DK0819135T3 (da) 2000-05-08
HUP9800513A3 (en) 1998-09-28
DE19512484A1 (de) 1996-10-17
US6271342B1 (en) 2001-08-07
DE59603678D1 (de) 1999-12-23
CA2217164A1 (en) 1996-10-10
NO974564D0 (no) 1997-10-02
EP0819135B1 (de) 1999-11-17
BG63048B1 (bg) 2001-02-28
ES2140078T3 (es) 2000-02-16
BR9604825A (pt) 1999-01-05
MX9707613A (es) 1997-12-31
NO974564L (no) 1997-11-25
SK134597A3 (en) 1998-05-06

Similar Documents

Publication Publication Date Title
BG101892A (bg) Цитостатици, модифицирани с въглехидрати
ZA9710098B (en) Halogenopyrimidines.
MY120511A (en) New pesticides
BG103914A (bg) Фармацевтичен състав с продължително освобождаване и неговото използаве
MXPA02004666A (es) Gelatinas recombinantes.
AP9400666A0 (en) Benzofuran derivatives.
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
IL114294A0 (en) Sterol derivatives
AU9744298A (en) Substituted tetrahydronaphthaline and analogous compounds
GB9003939D0 (en) Sulphatase inhibitors
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
HU9503370D0 (en) N-alkylthio polyamine derivatives as radioprotective agents
AU6682594A (en) Treatment of septic shock
BG100248A (bg) Инхибитори на скваленсинтетаза
AU4088097A (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta(b)benzofurans
AU4925200A (en) Oral composition containing perlite
MX9602836A (es) MEZCLA QUE CONTIENE UNO O VARIOS ALFA-AMINOACIDOS Y SUS DERIVADOS, O AMBOS, Y UNO O VARIOS CICLOPENTANO- beta-AMINOACIDOS Y SUS DERIVADOS, O AMBOS.
AU6832498A (en) Substituted benzyl oximino compounds
AU5419699A (en) Methoximinophenylacetic acid amides
YU62800A (sh) Postupak za proizvodnju r-(+)-6- karboksamido-3n-metilamino- 1,2,3,4-tetrahidrokarbazola
AU2910800A (en) Novel substituted 3-phenoxy and 3-phenylalkyloxy-2-phenyl-propylamines
AU9178198A (en) Diamond core with a diamond coating
PL312966A1 (en) Derivatives of thiocarbamoil
EP1306366A3 (en) New dibenzosuberone derivatives
UA16651A1 (uk) 1-1-феhил-2-метиламіhопропаhолу-1, 5, 6, 7-тріоксифлавоh-7-0-b-d-глюкуроhідат, що має аhтистресову активhість